We are live on ! Find out more
BLPH

Bellerophon Therapeutics, Inc.

Delisted

BLPH was delisted on the 13th of October, 2023.

23 hedge funds and large institutions have $825K invested in Bellerophon Therapeutics, Inc. in 2023 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

57% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 7

21% more funds holding

Funds holding: 1923 (+4)

97% less capital invested

Capital invested by funds: $27.9M → $825K (-$27.1M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1K

Holders
23
Holders Change
+4
Holders Change %
+21.05%
% of All Funds
0.36%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
11
Increased
6
Reduced
2
Closed
7
Calls
Puts
$1K
Net Calls
-$1K
Net Calls Change
-$1K

BLPH Hedge Fund Activity: Q2 2023 in Review

23 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q2 2023, worth a combined $825K — down 97% from $27.9M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new BLPH positions and 7 closed out — a net gain of 4 holders — while 6 added to existing stakes and 2 trimmed.

The largest buyer was Acadian Asset Management, opening a new position worth an estimated $1.71M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $7.34M sold.

  • 23 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q2 2023, up from 19 in Q1 2023.
  • Funds reported $825K of Bellerophon Therapeutics, Inc. stock for Q2 2023, down 97% quarter-over-quarter.
  • 11 funds opened new Bellerophon Therapeutics, Inc. positions in Q2 2023 and 7 closed out, a net change of +4 holders.
  • The largest Bellerophon Therapeutics, Inc. buyer in Q2 2023 was Acadian Asset Management, an estimated $1.71M added.
  • The largest Bellerophon Therapeutics, Inc. seller in Q2 2023 was Perceptive Advisors, an estimated $7.34M sold.

Based on aggregated 13F filings for Q2 2023.